Maxwell Enterprises

Category: Erectile Dysfunction (ED) treatment
Active Ingredient: Sildenafil Citrate 120 mg
Manufacturer: Varies by distributor (often from India)

Hiforce Cobra 120 mg is a high-strength oral tablet formulated to treat erectile dysfunction in men. It enhances blood flow to the penis, helping men achieve and maintain a firm erection during sexual stimulation.

• Higher dose than standard Sildenafil (50/100 mg)

• Suitable for patients not responsive to lower doses

• Distinctive "Cobra" branding for marketing appeal

30–60 minutes after ingestion

4–6 hours

• Headache

• Facial flushing

• Nasal congestion

• Dizziness

• Upset stomach

• Individuals with heart conditions taking nitrates

• Severe liver/kidney disease

• Women and children

Category: Female Sexual Dysfunction (FSD) support
Active Ingredient: Sildenafil Citrate (usually in 50–100 mg range)
Target Use: Women with low libido or arousal difficulties

Hiforce FM is designed for women and aims to improve genital blood flow, sensitivity, and sexual arousal. It is based on the action of Sildenafil but tailored for female physiology.

• Sometimes referred to as “female Viagra”

• May improve clitoral sensitivity and response to stimulation

• Best results when combined with psychological and hormonal support

45 minutes to 1 hour

4–5 hours

• Nausea

• Headache

• Flushing

• Dizziness

• Pregnant or breastfeeding women

• Individuals with hypotension or cardiovascular issues

• Use with caution and only under medical supervision

Additional Information:

• Delivery Time: 12-15 days

Additional Information:

• Item Code: MAXMD787
• Production Capacity: 10000
• Delivery Time: 8-10 days
• Packaging Details: Each strip has 10 tablets.

• We do have 250 mg and 500 mg in ABIRATERONE ACETATE.
• Abiraterone Acetate treats prostate cancer that has spread to other parts of the body.
• It must be taken empty stomach. Don't eat any food for at least 2 hours before or 1 hour after your dose.
• Do not break, crush, or chew the tablet before swallowing. Swallow it whole with a glass of water.
• Always use effective birth control measures to prevent pregnancy while taking this medicine.
• Abiraterone is used together with steroid medication (prednisone or methylprednisolone) to treat prostate cancer that has spread to other parts of the body. abiraterone is used in men whose prostate cancer cannot be treated with surgery or other medicines.

Additional Information:

• Delivery Time: 8-10 days

Generic Name: Alectinib Hydrochloride
Brand Name: Alecensa
Strength: 150 mg per capsule
Formulation: Hard gelatin capsule
Manufacturer: Roche
Indication: Treatment of ALK-positive non-small cell lung cancer (NSCLC)

Alectinib is a selective tyrosine kinase inhibitor that targets and inhibits the activity of the anaplastic lymphoma kinase (ALK) protein. By blocking ALK, alectinib disrupts the signaling pathways that promote the growth and survival of cancer cells, thereby inhibiting tumor progression in ALK-positive NSCLC.

Alecensa is indicated for:

• First-line treatment of adult patients with ALK-positive advanced or metastatic NSCLC.

• Adjuvant treatment following complete tumor resection in adult patients with ALK-positive NSCLC (tumors ≥4 cm or node-positive), as detected by an FDA-approved test.

• Treatment of adult patients with ALK-positive metastatic NSCLC previously treated with crizotinib.

• Recommended Dose: 600 mg (four 150 mg capsules) taken orally twice daily with food.

• Adjuvant Treatment Duration: Continue for 2 years or until disease recurrence or unacceptable toxicity.

• Metastatic NSCLC Treatment Duration: Continue until disease progression or unacceptable toxicity.

• Missed Dose: If a dose is missed, take it as soon as possible unless the next dose is due within 6 hours; do not take two doses at the same time to make up for a missed dose.

• Fatigue

• Constipation

• Peripheral edema (swelling)

• Rash

• Cough

These side effects are generally manageable and may resolve with continued therapy.

• Liver Problems: Symptoms may include nausea, loss of appetite, dark urine, yellowing of the skin or eyes.

• Lung Problems: Symptoms may include cough, shortness of breath, or fever.

• Kidney Problems: Symptoms may include changes in urine output or swelling in the legs or feet.

• Slow Heartbeat (Bradycardia): Symptoms may include dizziness or fainting.

• Muscle Problems: Symptoms may include unexplained muscle pain, tenderness, or weakness. 

• Storage Temperature: Store at 20°C to 25°C (68°F to 77°F).

• Protection: Keep in the original container to protect from moisture and light.

• Handling: Do not remove desiccant from the bottle.

• Sun Sensitivity: Alecensa may increase sensitivity to sunlight; use sunscreen and protective clothing.

• Drug Interactions: Avoid concurrent use with strong CYP3A inhibitors or inducers.

• Alcohol Consumption: Avoid alcohol during treatment.

• Breastfeeding: Consult a healthcare provider before breastfeeding.

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Calcium Folinate (Leucovorin Calcium)
Form: Injection (IV/IM)
Strength: 15 mg per vial

• Folate deficiency anemia: When oral therapy is not feasible or ineffective.

• Supportive therapy in cancer: Used with 5-fluorouracil (5-FU) to enhance its cytotoxic effect in colorectal and other cancers.

• Methotrexate toxicity prevention: Acts as a rescue agent in low-to-moderate methotrexate therapy.

• Overdose of folate antagonists like trimethoprim or methotrexate.

Calcium folinate is a reduced form of folic acid that bypasses dihydrofolate reductase, helping restore normal DNA/RNA synthesis in healthy cells without interfering with the action of chemotherapy drugs on cancer cells.

• Administered by intravenous or intramuscular injection.

• Dose depends on the protocol: e.g., 15 mg every 6 hours for methotrexate rescue or as per 5-FU combination schedules.

• Mild nausea or vomiting

• Allergic reactions (rare): rash, itching, or anaphylaxis

• Local injection site irritation or pain

Generic Name: Calcium Folinate (Leucovorin Calcium)
Form: Injection (IV/IM)
Strength: 50 mg per vial

• High-dose methotrexate rescue therapy: To prevent damage to normal cells by replenishing folate.

• Combination chemotherapy: With 5-FU for colorectal and GI cancers.

• Treatment of severe folate deficiency

• Antidote for folic acid antagonist toxicity

Same as 15 mg injection — bypasses blocked folic acid metabolism caused by certain chemotherapy agents, allowing healthy cells to recover and multiply normally.

• Typically given in hospital/oncology setups via IV injection, sometimes IM.

• Dosage can vary widely based on methotrexate blood levels and specific cancer treatment protocols.

• Frequently administered every 6 hours until methotrexate levels are safe.

• GI discomfort: nausea, vomiting, diarrhea

• Injection site reactions

• Hypersensitivity reactions (rare)

Additional Information:

• Delivery Time: 12-15 days

Capecitabine is a prodrug of 5-Fluorouracil (5-FU), meaning it's converted into 5-FU in the body. It selectively targets cancer cells and is used in:

• Breast cancer

• Colorectal cancer

• Stomach cancer (off-label use in some cases)

It's typically taken orally, and dosage depends on body surface area and patient condition.

• Manufacturer: Cipla (India)

• Form: Film-coated tablet

• Indications:

  • Metastatic breast cancer (especially post-anthracycline/taxane failure)

  • Colorectal cancer (metastatic or adjuvant)

• Recognition:
  ✅ Most widely prescribed brand in India and some other Asian and African countries.
  ✅ Often stocked in both public and private hospitals.

• Advantages:

  • Reliable supply chain

  • Backed by a reputed pharmaceutical brand

  • Frequently included in government tenders and hospital formulary lists

• Manufacturer: Intas Pharmaceuticals (India)

• Form: Tablet

• Indications:

  • Same as above: colorectal and breast cancer

• Recognition:
  ⚠️ Less widely known than Capeguard
  🔹 May be preferred in certain hospitals or regions based on pricing or contracts

• Advantages:

  • Trusted manufacturer

  • Competitive pricing, sometimes offered in bulk hospital orders

• Notes:

  • Can be a cost-effective alternative to Capeguard

  • Limited brand recall compared to Capeguard

• Manufacturer: Celon Labs (India)

• Form: Tablet

• Indications:

  • Same (breast, colorectal cancer)

• Recognition:
  ⚠️ Relatively lesser known compared to Capeguard and Capsy

• Advantages:

  • Often marketed for cost-efficiency

  • May be preferred by oncologists familiar with Celon Labs

• Notes:

  • Availability may be region-specific

  • Used in certain cancer hospitals that source directly from Celon

Additional Information:

• Delivery Time: 12-15 days

• Pregabalin 150 mg

Rahika 150 mg is a moderate-strength dose of Pregabalin, widely used for managing neuropathic pain, generalized anxiety disorder (GAD), fibromyalgia, and as adjunctive therapy in epilepsy. It offers an effective balance between pain relief and tolerability for most patients.

• Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system.

• This reduces excitatory neurotransmitter release (e.g., glutamate, norepinephrine, substance P), leading to:

  • Pain relief

  • Anxiolytic effects

  • Anticonvulsant activity

• Peripheral neuropathy (diabetic, post-herpetic)

• Fibromyalgia

• Generalized anxiety disorder

• Partial-onset seizures (as add-on therapy)

• Neuropathic pain due to spinal cord injury

• Usually taken once or twice daily

• Commonly prescribed as:

  • 150 mg once daily, or

  • 75 mg twice daily to reduce peak-side effects

• Effective in most moderate cases of nerve pain or anxiety

• Well tolerated in the majority of patients

• Fewer side effects than higher doses

• May improve sleep and mood

• Dizziness

• Drowsiness

• Dry mouth

• Blurred vision

• Weight gain (with prolonged use)

• Peripheral edema (rare)

• Pregabalin 200 mg

Rahika 200 mg is a higher dose of Pregabalin, typically used in patients who have not responded sufficiently to 150 mg or lower doses. It provides more potent relief from severe or chronic neuropathic pain, anxiety, or seizures but comes with a higher risk of side effects.

Same as Rahika 150 mg, but due to the higher dose, it provides greater inhibition of nerve hyperactivity, leading to stronger symptom control.

• Severe diabetic neuropathy

• Refractory fibromyalgia

• Severe anxiety symptoms

• Chronic nerve pain not relieved by lower doses

• In certain cases of adjunctive seizure treatment

• Often used after dose escalation, when lower doses are ineffective

• Taken once daily or split into 100 mg twice daily, based on patient tolerance

• Provides stronger pain and anxiety relief

• Helps in cases resistant to 150 mg or lower doses

• May improve functionality and quality of life in more severe cases

Additional Information:

• Delivery Time: 12-15 days

• Carbamazepine 150 mg

• Likely an immediate-release tablet

Biocarb 150 mg is a moderate-strength dose of Carbamazepine, commonly used for epilepsy, neuralgias, and bipolar disorder. It’s typically prescribed during dose titration or maintenance therapy, allowing doctors to adjust the total daily dose precisely and gradually.

Carbamazepine works by:

• Blocking voltage-gated sodium channels in the brain and spinal cord

• Reducing the excessive firing of neurons

• Resulting in:

  • Anticonvulsant effects (stops seizures)

  • Pain relief in nerve-related disorders

  • Mood stabilization in bipolar disorder

• Partial and generalized seizures

• Trigeminal neuralgia

• Glossopharyngeal neuralgia

• Bipolar disorder (manic phase)

• Neuropathic pain

• Often started at 100–200 mg/day, gradually increasing

• Biocarb 150 mg allows flexible splitting of daily doses (e.g., 150 mg BID = 300 mg/day)

• Preferred in:

  • New patients

  • Elderly

  • Sensitive individuals

• Allows precise dose titration

• Better tolerability during initiation

• Less risk of side effects compared to higher doses

• Can be used with other antiepileptics

• Drowsiness

• Nausea

• Carbamazepine 450 mg

• Likely a controlled-release (CR) or extended-release (XR) formulation

Celcarb 450 mg is a higher-dose formulation designed for long-term stable patients who have already been titrated up from lower doses. The controlled-release nature ensures steady blood levels throughout the day, improving efficacy and reducing side effects like peaks and troughs.

Same as Biocarb:

• Reduces neuronal hyperexcitability

• Prolongs refractory period of nerve cells

• Provides anticonvulsant, analgesic, and mood-stabilizing effects

• Chronic epilepsy requiring stable higher dosing

• Long-standing trigeminal neuralgia

• Maintenance therapy in bipolar disorder

• Patients needing simplified dosing schedule

• Usually taken once or twice daily

• Often prescribed after patient is stabilized on lower doses (e.g., 150 → 300 → 450 mg)

• Used for daily maintenance doses of 450–900 mg/day

• Reduced pill burden (fewer tablets/day)

• Better compliance

• Fewer fluctuations in drug levels

• Good for patients who experience side effects at dose peaks

Additional Information:

• Delivery Time: 12-15 days

• Malignant melanoma (advanced/metastatic)

• Hodgkin’s lymphoma (as part of ABVD regimen)

• Occasionally used for soft tissue sarcomas

Dacarbazine is a prodrug. In the liver, it's metabolized to active methyl diazonium ion, which alkylates DNA, causing:

• DNA crosslinking

• Inhibition of replication

• Cell death in rapidly dividing cancer cells

• IV infusion only (over 15–30 minutes)

• Often used in combination regimens (e.g., ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine)

• Severe nausea and vomiting

• Myelosuppression (low blood counts)

• Liver toxicity

• Photosensitivity

• Flu-like symptoms

Same as above:

• Metastatic melanoma

• Hodgkin’s lymphoma

• Occasionally used in soft tissue sarcoma or neuroendocrine tumors

• IV injection

• Intermediate strength used for specific dosing requirements

Same as other Dacarbazine formulations:

• Bone marrow suppression

• Gastrointestinal upset

• Rarely: hepatic necrosis, hypersensitivity reactions

• Used in higher dosing regimens for:

  • Metastatic melanoma

  • Hodgkin’s lymphoma (higher-weight patients)

  • Sarcomas and other solid tumors

• Requires reconstitution and IV infusion

• Doses based on body surface area (BSA)

• More convenient for high-dose regimens (e.g., >850 mg/day)

Same class effects:

• Severe nausea/vomiting (requires antiemetics)

• Bone marrow suppression

• Liver toxicity (monitor LFTs)

• Injection site reactions (rare but possible)

• Store vials at 15°C to 25°C (room temperature)

• Protect from light and moisture

• Once reconstituted, use within 8 hours if kept refrigerated

• Do not freeze

Additional Information:

• Delivery Time: 12-15 days

• First-line treatment of metastatic non-small cell lung cancer (NSCLC)

• Specifically in patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations

Dacomitinib is a second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks:

• EGFR (ErbB1)

• HER2 (ErbB2)

• HER4 (ErbB4)

This results in the inhibition of tumor cell proliferation and survival.

• 45 mg is the standard starting dose for most patients.

• Administered once daily continuously until disease progression or unacceptable toxicity.

• Diarrhea

• Rash and skin reactions

• Dry skin

• Mucositis (mouth sores)

• Nail infections

• Decreased appetite

• This dose is typically used as a reduced dose if the patient experiences moderate adverse effects with the 45 mg dose.

• May also be used as a maintenance dose after an initial response.

• To reduce toxicity while maintaining efficacy.

• Helps patients stay on treatment longer with better tolerability.

Similar to the 45 mg dose but often less intense due to the lower concentration:

• Mild to moderate diarrhea

• Skin dryness

• Appetite loss

• Lowest available dose for patients who cannot tolerate higher doses (45 or 30 mg).

• Often used as a last dose adjustment step before discontinuing treatment due to side effects.

• After multiple dose reductions from 45 → 30 → 15 mg

• In frail or elderly patients who are more susceptible to side effects

• Mild side effects

• Preferred when higher doses cause intolerable toxicity

Additional Information:

• Delivery Time: 12-15 days

Alsatinib

Tyrosine kinase inhibitor (TKI)

• Treatment of ALK-positive non-small cell lung cancer (NSCLC)

• 20 mg dose often used for starting or dose adjustment

• Blocks ALK enzyme to stop cancer growth and spread

• Oral tablet, usually once daily

• Fatigue, nausea, diarrhea

• Elevated liver enzymes

• Cough, shortness of breath

• Swelling (edema)

Dasatinib

Tyrosine kinase inhibitor (TKI)

• Chronic myeloid leukemia (CML)

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

• Inhibits BCR-ABL kinase to block leukemia cell growth

• Oral tablet, once or twice daily

• Fluid retention and swelling

• Fatigue, headache

• Low blood counts (myelosuppression)

• Bleeding risk

Nintedanib

Tyrosine kinase inhibitor & antifibrotic agent

• Idiopathic pulmonary fibrosis (IPF)

• Some lung cancers as combination therapy

• Inhibits VEGFR, PDGFR, FGFR to reduce fibrosis and tumor blood supply

• Oral capsule, twice daily

• Diarrhea, nausea

• Liver enzyme elevation

• Increased bleeding risk

Nintedanib or similar multi-kinase inhibitor

Multi-kinase inhibitor

• Idiopathic pulmonary fibrosis (IPF)

• Certain lung cancers

• Blocks angiogenesis and fibrosis pathways (VEGFR, PDGFR, FGFR)

• Oral, twice daily

• Gastrointestinal upset (diarrhea, nausea)

• Liver issues

• Bleeding/clotting risks

Additional Information:

• Delivery Time: 12-15 days

• Each vial or injection contains Fosphenytoin Sodium, a prodrug that delivers the equivalent of 150 mg phenytoin.

• Fosphenytoin is rapidly converted in the body to phenytoin, an anticonvulsant drug.

• Phenytoin acts by stabilizing neuronal membranes and limiting seizure activity through inhibition of voltage-dependent sodium channels. This action reduces the ability of neurons to fire at high frequency and helps control seizures.

• Treatment of generalized tonic-clonic seizures and complex partial seizures.

• Emergency management of status epilepticus (a prolonged seizure).

• Alternative to phenytoin for intravenous or intramuscular administration due to improved solubility and reduced risk of local irritation.

• IV or IM injection: Rapid onset makes it ideal for emergency use.

• Loading dose typically ranges from 10 to 20 mg phenytoin equivalents per kg body weight, infused slowly (usually not faster than 150 mg phenytoin equivalents per minute IV).

• Maintenance doses vary depending on seizure control and patient response.

• Must be administered under medical supervision with cardiac and respiratory monitoring.

• Common: Dizziness, headache, nausea, hypotension (especially with rapid IV infusion), injection site pain or irritation.

• Serious: Cardiac arrhythmias, severe hypotension, Stevens-Johnson syndrome (rare hypersensitivity), blood dyscrasias.

• Contraindicated in patients with hypersensitivity to phenytoin or fosphenytoin.

• Use caution in patients with heart conditions due to risk of arrhythmias.

• Each tablet contains 150 mg of Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor.

• Apremilast selectively inhibits PDE4, an enzyme involved in the breakdown of cyclic AMP (cAMP) inside immune cells.

• Increased cAMP modulates the production of inflammatory cytokines such as TNF-alpha, IL-23, and IL-17, reducing inflammation.

• This immune modulation helps control autoimmune conditions by balancing pro- and anti-inflammatory mediators.

• Approved for treatment of moderate to severe plaque psoriasis.

• Treatment of active psoriatic arthritis.

• Sometimes used off-label for other inflammatory or autoimmune disorders like Behçet's disease.

• Administered orally, typically 30 mg twice daily after a gradual titration schedule to reduce gastrointestinal side effects.

• Dose adjustments may be needed based on tolerance, renal function, or side effects.

• Treatment response usually evaluated after 12-16 weeks.

• Common: Diarrhea, nausea, headache, upper respiratory infections, weight loss, decreased appetite.

• Serious: Depression or suicidal ideation (rare but reported), hypersensitivity reactions.

• Not recommended in patients with severe renal impairment without dose adjustment.

• Use cautiously in patients with a history of depression or mood disorders.

Additional Information:

• Delivery Time: 12-15 days

• Gefitinib 250 mg per tablet

• Gefitinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI)

• It selectively blocks the epidermal growth factor receptor, which is often mutated and overactive in some non-small cell lung cancers (NSCLC)

• This prevents cancer cells from proliferating and promotes apoptosis (cell death)

• First-line treatment of locally advanced or metastatic NSCLC with EGFR mutation-positive tumors

• Especially effective in non-smokers, women, and East Asian patients with adenocarcinoma subtype

• 250 mg orally once daily, with or without food

• Usually packed in blisters of 10 tablets per strip or packs of 30 tablets

• Rash, diarrhea, nausea, vomiting

• Elevated liver enzymes

• Rare but serious: Interstitial lung disease (ILD), hepatotoxicity

• Liver function monitoring required

• Check EGFR mutation status before use

• Not for use in patients without EGFR mutations

• Store at room temperature (15–30°C), in a dry place away from direct light

• Gefitinib 250 mg per tablet (same as Geffy)

• Same therapeutic indication: EGFR mutation-positive NSCLC

• Generic version of Gefitinib

• Manufactured by different pharmaceutical companies

• Often more cost-effective, used in settings with budget constraints

• Similar packaging: Blister or bottle packs

• Same oral administration and dosage

• Efficacy is comparable in many cases, but prescriber preference may favor branded Geffy due to longer market presence and better pharmacovigilance data.

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Hydroxyurea
Strength: 500 mg
Form: Capsule
Manufacturer: Celon Laboratories Ltd.
ATC Code: L01XX05

• Chronic Myeloid Leukemia (CML)

• Polycythemia Vera

• Sickle Cell Anemia

• Cervical Cancer

• Ovarian Cancer

• Head and Neck Cancers

Hydroxyurea inhibits ribonucleotide reductase, halting DNA synthesis and cell replication—especially effective against rapidly dividing malignant cells and beneficial in modifying red blood cell characteristics in sickle cell disease.

• Commonly supplied in blister strips or bottles

• 10 capsules per strip (varies by supplier)

• Store below 25°C

• Keep away from moisture and light

• Typically 24 to 36 months

Generic Name: Hydroxyurea
Strength: 500 mg
Form: Capsule
Manufacturer: Gem Pharmaceuticals

• Chronic Myeloid Leukemia (CML)

• Sickle Cell Anemia

• Essential Thrombocythemia

• Polycythemia Vera

• Cervical Cancer

• Ovarian Cancer

• Head and Neck Cancers

Functions similarly by inhibiting DNA synthesis in cancer cells. In sickle cell patients, it increases fetal hemoglobin (HbF) levels, reducing complications like painful vaso-occlusive crises.

• Supplied in bottles or blister packs

• 10 or 30 capsules per pack (varies)

• Store in a cool, dry place

• Protect from direct light and humidity

• Typically 24 to 36 months

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Ibrutinib
Manufacturer: Generic (varies by region; typically by Indian pharmaceutical companies)
Form: Capsule
Strength: 140 mg

Ib-Tib 140 mg is prescribed for the treatment of:

• Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

• Mantle Cell Lymphoma (MCL) – in patients who have received at least one prior therapy

• Waldenström's Macroglobulinemia (WM)

• Marginal Zone Lymphoma (MZL)

• Chronic Graft Versus Host Disease (cGVHD)

Ibrutinib is a Bruton's Tyrosine Kinase (BTK) inhibitor. It blocks BTK, a protein crucial for B-cell proliferation and survival, thereby inhibiting cancerous B-cell growth.

• Dosage varies based on condition (commonly 420 mg to 560 mg/day) → typically 3–4 capsules daily

• Diarrhea, nausea, bleeding, infections

• Low blood cell counts

• Atrial fibrillation (in rare cases)

• Supplied in blisters or bottles, typically 30 or 120 capsules

Generic Name: Ibrutinib
Manufacturer: Emcure Pharmaceuticals Ltd.
Form: Capsule
Strength: 140 mg

Identical to Ib-Tib, used for:

• Chronic Lymphocytic Leukemia (CLL) / SLL

• Mantle Cell Lymphoma (MCL)

• Waldenström’s Macroglobulinemia (WM)

• Marginal Zone Lymphoma (MZL)

• Chronic GVHD (cGVHD)

Same BTK inhibition as Ib-Tib — blocks B-cell receptor signaling pathway, leading to reduced cancer cell proliferation.

• Based on the condition (commonly 420 mg/day for CLL, 560 mg/day for MCL)

• Hemorrhage, neutropenia, atrial fibrillation

• Rash, fatigue, musculoskeletal pain

• Increased infection risk

• Available in HDPE bottles or blister packs containing 30/90/120 capsules

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Ifosfamide
Brand Name: Ifex-M
Strength: 1 g (1,000 mg)
Form: Lyophilized powder for injection
Route of Administration: Intravenous (IV)

Ifosfamide is an alkylating agent (nitrogen mustard class) that:

• Interferes with DNA replication

• Forms DNA crosslinks, preventing cell division

• Induces apoptosis in rapidly dividing cancer cells

• Testicular cancer

• Soft tissue sarcomas

• Non-Hodgkin’s lymphoma

• Cervical and ovarian cancers

• Osteosarcoma

• Neuroblastoma (pediatric)

• Usually given in doses of 1–2 g/m²/day for 3–5 days

• Mesna is co-administered to prevent bladder toxicity

• Used as monotherapy or in combination chemotherapy protocols (e.g., with cisplatin, doxorubicin)

• Hemorrhagic cystitis (mitigated with Mesna)

• Nausea, vomiting

• Myelosuppression

• Neurotoxicity (confusion, encephalopathy)

• Alopecia

• Supplied as a single-dose vial with 1 g of Ifosfamide powder

• Requires reconstitution before IV infusion

• 24 to 36 months when stored properly at controlled room temperature (15–25°C)

Generic Name: Ifosfamide
Brand Name: Ifomid-M
Strength: 2 g (2,000 mg)
Form: Lyophilized powder for injection
Route of Administration: Intravenous (IV)

• Used in high-dose chemotherapy regimens

• Typically administered in hospital oncology centers

• Indicated for more aggressive cancers or relapsed/refractory tumors

• Higher dose per vial allows for reduced vial usage during high-dose protocols

• Requires more rigorous hydration and supportive therapy to avoid toxicity

• Mesna is mandatory to prevent bladder toxicity

• All side effects of Ifex-M 1 g, but may be more severe due to higher concentration:

  • Bladder toxicity

  • Neurotoxicity

  • Myelosuppression

  • Electrolyte imbalances

• Vial containing 2 g of Ifosfamide powder

• Also needs reconstitution for IV infusion

• Typically 24–36 months if stored in a cool, dry place

Additional Information:

• Delivery Time: 12-15 days

Generic Name: (Typically, based on similar naming, might be Naproxen or a related NSAID, but please confirm with exact active ingredient)

Dosage Form: Tablet/Capsule

Strength: 40 mg

Indications:

• Management of mild to moderate pain

• Anti-inflammatory treatment for conditions such as arthritis, musculoskeletal disorders

• Fever reduction

Description:
Irnocam 40 mg is generally a lower-strength anti-inflammatory or analgesic medication used to manage pain and inflammation. It is commonly prescribed for patients requiring milder doses or those who may not tolerate higher doses. The medication works by inhibiting enzymes involved in inflammation pathways (such as COX-1 and COX-2 in NSAIDs), thereby reducing pain and swelling.

Mechanism of Action:
Blocks prostaglandin synthesis by inhibiting cyclooxygenase enzymes, reducing inflammation and pain.

Administration:
Oral use, typically 1-2 times daily, depending on physician’s instructions.

Common Side Effects:

• Gastrointestinal upset (nausea, dyspepsia)

• Mild headache

• Dizziness

• Rare: gastric ulcers or bleeding with prolonged use

Manufacturer: (Please specify, as this can vary)

Generic Name: (Likely a stronger anti-inflammatory or analgesic drug, possibly a higher dose of same active ingredient or different medication like Diclofenac, or a stronger NSAID—please specify exact active ingredient for accuracy)

Dosage Form: Tablet/Capsule

Strength: 100 mg

Indications:

• Moderate to severe pain management

• Inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and severe musculoskeletal disorders

• Post-operative pain relief

Description:
Intensic 100 mg is a higher-strength analgesic or anti-inflammatory medication designed for more severe cases where a stronger dose is required. It effectively reduces pain and inflammation by inhibiting the production of inflammatory mediators. Due to its higher dose, it is generally reserved for adult patients or cases requiring significant symptom control.

Mechanism of Action:
Inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis, alleviating pain and inflammation.

Administration:
Oral, often once or twice daily as prescribed.

Common Side Effects:

• Gastrointestinal disturbances (nausea, vomiting, abdominal pain)

• Risk of ulcers or bleeding with prolonged use

• Headache, dizziness

• Potential cardiovascular risks with long-term use

Manufacturer: (Please specify)

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Lamivudine
Dosage Form: Tablet
Strength: 250 mg

• Treatment of Human Immunodeficiency Virus (HIV-1) infection as part of combination antiretroviral therapy.

• Treatment of Chronic Hepatitis B infection.

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). It works by inhibiting the reverse transcriptase enzyme, which is essential for viral replication in both HIV and Hepatitis B viruses. This inhibition reduces viral load and slows disease progression.

• Oral, typically once or twice daily as part of combination therapy.

• Dose and duration depend on clinical response and co-administered drugs.

• Headache

• Fatigue

• Nausea

• Diarrhea

• Cough

• Rarely, lactic acidosis and hepatomegaly with steatosis (especially with prolonged use).

Cadila Pharmaceuticals Ltd.

Generic Name: Lamivudine
Dosage Form: Tablet
Strength: 250 mg

• Part of antiretroviral regimens for HIV-1 infection.

• Used in chronic Hepatitis B virus infection management.

Lamivudine acts as a synthetic nucleoside analog that competes with natural nucleosides to inhibit reverse transcriptase, thus blocking viral DNA synthesis and viral replication.

• Oral intake, usually once or twice daily combined with other antiretroviral drugs.

• Dosage tailored to patient needs and treatment protocol.

• Mild gastrointestinal symptoms (nausea, diarrhea)

• Headache

• Fatigue

• Rare occurrences of serious side effects like lactic acidosis.

Lupin Limited

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Thalidomide
Dosage Form: Capsule/Tablets
Strength: 250 mg

• Multiple Myeloma

• Erythema Nodosum Leprosum (ENL)

• Other hematologic malignancies

Celomide contains thalidomide, an immunomodulatory drug that inhibits angiogenesis and modulates immune response. It reduces tumor growth and inflammation but requires strict pregnancy prevention due to teratogenicity.

• Inhibits blood vessel formation (anti-angiogenic)

• Modulates cytokines and enhances immune cell activity

• Suppresses tumor necrosis factor-alpha (TNF-α)

• Oral, once daily or as prescribed

• Requires strict pregnancy prevention

• Peripheral neuropathy (tingling, numbness)

• Sedation/drowsiness

• Constipation

• Dizziness

• Rash

• Risk of blood clots

Various, including Intas Pharmaceuticals Ltd.

Generic Name: Lenalidomide
Dosage Form: Capsule/Tablets
Strength: 5 mg

• Multiple Myeloma

• Myelodysplastic Syndromes (MDS)

• Mantle Cell Lymphoma (MCL)

Laviat contains lenalidomide, a safer and more potent derivative of thalidomide with stronger immunomodulatory and anti-cancer effects, commonly used in hematologic cancers.

• Stimulates T-cells and NK cells

• Inhibits pro-inflammatory cytokines (TNF-α)

• Blocks angiogenesis

• Promotes apoptosis of cancer cells

• Oral, once daily, with or without food

• Dose adjusted for kidney function and blood counts

• Low white blood cells (neutropenia)

• Anemia

• Fatigue

• Diarrhea or constipation

• Blood clot risk

Intas Pharmaceuticals Ltd. and others.

Generic Name: Lenalidomide
Dosage Form: Capsule/Tablets
Strength: 10 mg

• Multiple Myeloma

• Myelodysplastic Syndromes (MDS)

• Mantle Cell Lymphoma (MCL)

Lenome 10 mg is a higher-strength lenalidomide tablet, used for patients needing higher doses to control hematologic cancers effectively.

• Same as Laviat 5 mg: immunomodulation, anti-angiogenesis, apoptosis induction

• Oral, once daily or as prescribed

• Dose adjusted based on patient response

• Similar to Laviat 5 mg: neutropenia, anemia, fatigue, GI issues, clot risk

Intas Pharmaceuticals Ltd. and others.

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Doxorubicin Hydrochloride Liposomal
Strength: 10 mg
Formulation: Liposomal Injection
Manufacturer: Sun Pharma

• Metastatic Breast Cancer

• Ovarian Cancer

• AIDS-related Kaposi’s Sarcoma

• Multiple Myeloma (in combination therapy)

Doxorubicin intercalates DNA and inhibits topoisomerase II, preventing replication and transcription. The liposomal form ensures targeted delivery and reduced cardiotoxicity.

• Intravenous infusion

• Dosed based on body surface area (BSA)

• Slower infusion recommended to avoid infusion-related reactions

• Palmar-plantar erythrodysesthesia (hand-foot syndrome)

• Nausea

• Fatigue

• Mucositis

• Myelosuppression (anemia, neutropenia)

Refrigerated (2°C – 8°C); do not freeze.

24–36 months under recommended storage.

• Reduced cardiotoxicity compared to conventional doxorubicin

• Preferred in patients with cardiac risk

Generic Name: Doxorubicin Hydrochloride Liposomal
Strength: 20 mg
Formulation: Liposomal Injection
Manufacturer: Miracalus Pharma

• Breast Cancer

• Ovarian Cancer

• Multiple Myeloma

• Kaposi’s Sarcoma

Same as Lipodox – uses liposomal technology to encapsulate doxorubicin for improved safety and targeted action, enhancing drug accumulation in tumor tissues.

• Intravenous infusion

• Typically once every 3 to 4 weeks

• Rash

• Mouth sores

• Anemia

• Fatigue

• Low blood counts

Approximately 2 years

• Comparable to Lipodox

• Slightly higher strength (20 mg) per vial provides flexibility in dosing

Generic Name: Doxorubicin Hydrochloride (Conventional)
Strength: 50 mg
Formulation: Conventional (non-liposomal) Injection
Manufacturer: Cipla Ltd.

• Leukemias (ALL, AML)

• Breast and Ovarian Cancers

• Bladder Cancer

• Lung Cancer

• Hodgkin and Non-Hodgkin Lymphomas

Doxorubicin binds DNA and inhibits topoisomerase II → DNA damage → cell death. Not liposomal, so higher systemic exposure and increased cardiotoxicity risk.

• IV push or short infusion over a few minutes

• Often used in combination chemotherapy regimens

• Cardiotoxicity (cumulative dose dependent)

• Hair loss

• Bone marrow suppression

• Mucositis

• Red-colored urine (normal)

Usually 2–3 years

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Melphalan
Class: Alkylating Agent (Chemotherapy)
Form: Tablet
Strength: 50 mg

🔬 What It’s Used For:

• Multiple Myeloma

• Ovarian Cancer

• Occasionally used in conditioning before bone marrow transplants

⚙️ How It Works:
Melphalan works by damaging the DNA of cancer cells, which prevents them from growing and dividing. It is part of a group of chemotherapy drugs known as alkylating agents.

🧪 Dosage & Administration:

• Typically prescribed under careful supervision by an oncologist.

• Oral use, often in cycles or in combination with other chemotherapy drugs.

⚠️ Side Effects:

• Nausea, vomiting

• Bone marrow suppression (low blood counts)

• Mouth sores

• Risk of infection

• Hair thinning

📌 Notes:

• Requires regular blood tests to monitor blood cell counts.

• Not to be taken without medical supervision.

Generic Name: Melphalan
Class: Alkylating Agent (Chemotherapy)
Form: Tablet
Strength: 2 mg

🔬 What It’s Used For:

• Multiple Myeloma

• Breast or ovarian cancer (in specific treatment plans)

⚙️ How It Works:
Alkacel, like Melfalax, contains melphalan, and functions by damaging the DNA of cancer cells, which slows or stops their growth.

🧪 Dosage & Administration:

• Lower dose compared to Melfalax, often used in long-term treatment or for patients requiring dose adjustments.

• Must be taken as prescribed—timing and dosage are crucial.

⚠️ Side Effects:

• Low white/red blood cell count

• Loss of appetite

• Diarrhea or constipation

• Risk of secondary cancers (long-term use)

📌 Notes:

• Take on an empty stomach, or as advised by the oncologist.

• Store in a cool, dry place.

Generic Name: Melphalan
Class: Alkylating Agent (Chemotherapy)
Form: Tablet
Strength: 5 mg

🔬 What It’s Used For:

• Multiple Myeloma

• Advanced ovarian cancer

• Occasionally for polycythemia vera or other rare conditions

⚙️ How It Works:
Alphalan also contains melphalan and works by creating cross-links in DNA strands, leading to cell death in rapidly growing cancer cells.

🧪 Dosage & Administration:

• Often used in long-term management or combination regimens.

• Must be taken exactly as prescribed—missed doses can reduce effectiveness.

⚠️ Side Effects:

• Suppressed immune function

• Increased risk of infections

• Nausea and fatigue

• Possible fertility issues

Additional Information:

• Delivery Time: 12-15 days

• Contains paclitaxel dissolved in Cremophor EL (polyoxyethylated castor oil) and ethanol.

• Breast cancer (especially after failure of anthracycline therapy)

• Ovarian cancer

• Non-small cell lung cancer (with platinum-based agents)

• IV infusion, typically over 3 hours

• Requires premedication with corticosteroids, antihistamines, and H2 blockers to reduce risk of hypersensitivity due to Cremophor EL.

• Similar solvent system as Celtax: Cremophor EL and ethanol

• Same as Celtax; used in various solid tumors including breast, ovarian, lung cancers

• Lower dose vial (260 mg), which may be preferred based on body surface area (BSA) and patient need.

• Possibly produced by a different pharmaceutical company

• Standard solvent formulation with Cremophor EL

• Often used when low-dose therapy is required:

  • For dose adjustments

  • In elderly or frail patients

  • In weekly dosing regimens 

• No Cremophor EL → reduced hypersensitivity

• Nanoparticle delivery → improved tumor uptake    

• ✅ Mitotax 250 mg

• _{🔹 Generic Name: Paclitaxel🔹 Brand Name: Mitotax🔹 Strength: 250 mg per vial🔹 Formulation: Conventional Paclitaxel Injection🔬 Composition}

  • _{Paclitaxel 250 mg in a solution of:}

    • _{Cremophor EL (polyethoxylated castor oil)}

    • _{Dehydrated alcohol (ethanol)}

  • _{Supplied as a concentrated solution for intravenous (IV) infusion}

  _{💊 Indications / Uses}

  _{Mitotax is widely used in the treatment of solid tumors, particularly:}

  1. _{Breast Cancer – often after anthracycline failure or as part of combination therapy}

  2. _{Ovarian Cancer – frontline therapy with cisplatin/carboplatin or after relapse}

  3. _{Non-Small Cell Lung Cancer (NSCLC) – in combination with platinum agents}

  4. _{Kaposi’s Sarcoma – in HIV-positive patients}

  5. _{Other off-label or trialed uses: bladder, head and neck, and esophageal cancers.}

Additional Information:

• Delivery Time: 12-15 days

• Active Ingredient: Alendronate sodium

• Strength: 30 mg tablet

• Drug Class: Bisphosphonate

• Mechanism of Action:
  Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone, leading to increased bone mineral density and decreased fracture risk. It slows bone loss and promotes bone strength.

• Indications:

  • Treatment and prevention of postmenopausal osteoporosis.

  • Treatment of osteoporosis in men.

  • Treatment of Paget’s disease of bone.

• Dosage:

  • Usually prescribed as a daily dose of 10 mg or 30 mg (for certain conditions or higher risk patients).

  • Taken orally once daily with a full glass of water at least 30 minutes before the first food, drink, or medication of the day.

• Side Effects:

  • Gastrointestinal irritation (esophagitis, gastritis).

  • Abdominal pain, nausea.

  • Rare: osteonecrosis of the jaw, atypical femur fractures.

• Precautions:

  • Patients must remain upright for at least 30 minutes after taking to prevent esophageal irritation.

  • Adequate calcium and vitamin D intake recommended.

• Storage:
  Store at room temperature, away from moisture and heat.

• Active Ingredient: Alendronate sodium

• Strength: 60 mg tablet

• Usage:

  • Less commonly used as a daily dose.

  • Sometimes prescribed as a weekly dose (e.g., 70 mg weekly is common in some brands, so 60 mg may be a variant).

• Indications:
  Similar to 30 mg but often for convenience of less frequent dosing in osteoporosis management.

• Administration:
  Oral, once weekly dosing is typical with higher strengths to improve compliance.

• Side Effects & Precautions:
  Similar to 30 mg.

• Active Ingredient: Alendronate sodium

• Strength: 90 mg tablet

• Usage:

  • Generally less common; may be used for monthly dosing regimens in some cases (though 70 mg weekly is the most common higher dose).

  • Sometimes prescribed in special cases or formulations depending on physician preference or country-specific guidelines.

• Indications:
  Same as above: osteoporosis treatment and prevention, Paget’s disease.

• Administration:
  Oral, usually with instructions similar to other doses regarding fasting and posture after taking.

• Side Effects & Precautions:
  Same as lower doses.

Additional Information:

• Delivery Time: 12-15 days

• Advanced renal cell carcinoma (RCC)

• Advanced soft tissue sarcoma (STS) after prior chemotherapy

• Often used as part of dose-adjusted therapy

• Can be combined to form the full 800 mg daily dose, depending on tolerance

• Diarrhea, nausea

• Hypertension

• Liver enzyme elevation

• Hair color lightening

• Fatigue

• Risk of hepatotoxicity and QT prolongation

• Store below 30°C in original packaging

• Protect from moisture and light

• First-line therapy for renal cell carcinoma

• Second-line treatment for soft tissue sarcoma

• 800 mg once daily (usually taken as two 400 mg tablets)

• Taken on an empty stomach (at least 1 hour before or 2 hours after food)

• Similar to Pazeqol: GI issues, fatigue, liver function abnormalities

• May cause serious liver problems — LFT monitoring required

• Proteinuria, bleeding, and cardiac events possible in rare cases

• Store at 15–30°C

• Keep away from children and pets

Pazib 400 mg is widely used due to reduced pill burden (vs. multiple 200 mg tablets).

• Same as other pazopanib brands

• Used where dose reduction is required or for combination with other dosing strategies

• Individualized based on toxicity and tolerance

• Used to taper doses in 200 mg increments (e.g., reducing from 800 → 600 → 400 mg)

• Comparable to others: high blood pressure, altered taste, hepatotoxicity

• Frequent monitoring is required

• Store below 25°C

• Keep in original packaging

• Advanced renal carcinoma

• Advanced soft tissue sarcoma

• Typically 800 mg once daily (2 tablets of 400 mg)

• Used in standard-dose regimens

• Similar profile: GI upset, liver enzyme elevations, alopecia, hypertension

• Periodic ECG and LFT monitoring advised

• Store at controlled room temperature (15–30°C)

Additional Information:

• Delivery Time: 12-15 days

Carfilzomib

Amgen / Onyx Pharmaceuticals

Proteasome inhibitor (Selective for 20S proteasome, chymotrypsin-like activity)

Kyprolis is used:

• In combination with lenalidomide and dexamethasone

• In combination with dexamethasone alone

• For patients who have received 1–3 prior lines of therapy

• In relapsed/refractory multiple myeloma

• Carfilzomib irreversibly inhibits the 20S proteasome.

• This leads to accumulation of damaged proteins inside myeloma cells, causing apoptosis (cell death).

• More selective and potent than bortezomib, with reduced peripheral neuropathy risk.

• IV infusion over 10–30 minutes, 1–2 times per week

• 60 mg vial (reconstituted with sterile water)

• Dosage may vary (20 mg/m² → 56 mg/m²) based on cycle and patient response

• Store refrigerated at 2–8°C

• Once reconstituted, must be used within 24 hours

• FDA & EMA approved

• Part of first-line or second-line therapy

• Backed by large Phase 3 trials (e.g., ASPIRE, ENDEAVOR)

• Lower incidence of neuropathy compared to bortezomib

• Hypertension

• Dyspnea

• Cardiac events (rare but serious)

• Thrombocytopenia

• Anemia

• Fatigue

• High-cost branded medication

• Covered under many hospital reimbursement schemes or insurance plans in developed countries

Carfilzomib

Various generic or regional pharmaceutical companies, e.g., in India

Same as Kyprolis – Proteasome inhibitor

• Also indicated for relapsed or refractory multiple myeloma

• Bioequivalent generic version of Kyprolis

• May be substituted in resource-limited or cost-conscious settings

Identical to Kyprolis:

• Irreversible inhibition of the 20S proteasome

• Disrupts protein turnover → induces cancer cell death

• Same dosage patterns as Kyprolis:

  • IV infusion, 1–2x/week depending on protocol

  • Requires reconstitution

• Store below 25°C or as per manufacturer’s label

• Use immediately or within stability window post-reconstitution

• More affordable than Kyprolis

• Can be integrated into standard regimens if available and approved

• Offers access in low- and middle-income countries (LMICs)

Additional Information:

• Delivery Time: 12-15 days

Dabrafenib is used to treat cancers that have a BRAF V600E or V600K mutation, including:

• Unresectable or metastatic melanoma

• Non-small cell lung cancer (NSCLC)

• Anaplastic thyroid cancer (ATC)

• In combination with trametinib for certain indications to delay disease progression or resistance

 Only effective in tumors with BRAF V600 mutation — confirmed by genetic testing before treatment.

Dabrafenib inhibits mutated BRAF kinase, a component of the MAPK/ERK signaling pathway involved in cell proliferation.

• Blocks aberrant BRAF signaling

• Prevents cancer cell growth

• Induces apoptosis in tumor cells with the BRAF mutation

• Typical dose: 150 mg twice daily (combining three 50 mg capsules per dose)

• Administered orally, on an empty stomach (1 hour before or 2 hours after food)

• Can be combined with Trametinib (a MEK inhibitor) for improved outcomes

• Fever

• Fatigue

• Hyperkeratosis

• Arthralgia (joint pain)

• Rash

• Headache

• Nausea

• Alopecia

• Cough

Serious but less common:

• Febrile drug reaction

• Secondary skin cancers (keratoacanthoma, SCC)

• Hyperglycemia

• Uveitis, iritis

• QT prolongation

• Liver function tests

• Blood glucose levels

• Skin exams (for new lesions)

• Eye exams (if symptoms arise)

• Store at below 30°C (86°F)

• Keep in the original container to protect from moisture

• Do not refrigerate

• Keep out of reach of children

• Typically 24 months from the manufacturing date if stored properly (check packaging for confirmation)

Additional Information:

• Delivery Time: 12-15 days

Used to treat:

• Metastatic castration-resistant prostate cancer (mCRPC)

• Non-metastatic castration-resistant prostate cancer (nmCRPC)

• Metastatic hormone-sensitive prostate cancer (mHSPC)

• Typically, the standard enzalutamide daily dose is 160 mg.

• Enzyl 40 mg is used when flexible dosing is required.

• Example: 4 capsules of 40 mg = 160 mg daily.

• Ideal for titrating doses or patients needing individualized treatment.

• Less convenient than higher strength due to multiple capsule requirement.

Same indications as above—used for all stages of advanced prostate cancer under androgen deprivation therapy.

• 2 capsules of Enzamide 80 mg provide the standard 160 mg/day dose.

• Offers a middle-ground between 40 mg and 160 mg strengths.

• Suitable for moderate dose adjustments.

• Fewer capsules than Enzyl, improving compliance.

• Standard treatment for:

  • mCRPC (metastatic castration-resistant prostate cancer)

  • mHSPC (metastatic hormone-sensitive prostate cancer)

  • nmCRPC (non-metastatic castration-resistant prostate cancer)

• One 160 mg tablet once daily (standard adult dose)

• Can be taken with or without food.

• Most widely used and preferred due to:

  • Convenience (1 tablet/day)

  • Improved adherence

  • Direct match to standard treatment protocol

Additional Information:

• Delivery Time: 12-15 days

Celon Laboratories Ltd.

Each tablet contains Exemestane 25 mg

• Treatment of early and advanced hormone-receptor positive breast cancer in postmenopausal women

• Commonly used after 2–3 years of tamoxifen therapy as part of a sequential hormone treatment regimen

Exemestane is a steroidal aromatase inhibitor. It works by irreversibly inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogen. By lowering estrogen levels, it helps slow or stop the growth of hormone-sensitive tumors.

• 25 mg once daily after a meal

• Duration and continuation depend on response and oncologist’s direction

• Hot flashes

• Fatigue

• Joint/muscle pain (arthralgia/myalgia)

• Nausea

• Insomnia

• Increased sweating

• Typically available in strips of 10 tablets

• Store at room temperature (15–30°C), away from moisture and light

• Usually 24 months from the date of manufacture

Alkem Laboratories Ltd.

Each tablet contains Exemestane 25 mg

• Used for the treatment of advanced breast cancer in postmenopausal women

• Prescribed when the cancer progresses after tamoxifen therapy

As a steroidal aromatase inactivator, Exemestane binds permanently to aromatase, suppressing estrogen production—thereby slowing or reversing tumor progression in estrogen-dependent cancers.

• 25 mg orally once daily, preferably with food

• Joint and bone pain

• Mood changes, depression

• Headache

• Hot flashes

• Gastrointestinal disturbances

• Supplied in blister packs of 10 tablets

• Store below 30°C, protect from moisture and direct sunlight

• Typically 24 to 36 months

Additional Information:

• Delivery Time: 12-15 days

• Gemcitabine Hydrochloride, equivalent to 1.2 grams (1200 mg) of Gemcitabine

• Single-dose vial, Infusmart™ (ready-to-infuse formulation)

• Pre-diluted in a sterile infusion solution (varies by manufacturer)

• Widely used in:

  • Non-Small Cell Lung Cancer (NSCLC)

  • Pancreatic Cancer

  • Bladder Cancer

  • Breast and Ovarian Cancer

• Typically administered as part of cyclic chemotherapy regimens

• Preferred dose strength for adult patients with average body surface area (BSA ~1.6–1.8 m²)

• Ready-to-use infusion formulation

• Reduces preparation time

• Minimizes drug wastage

• Consistent with most standard chemotherapy dosing protocols

• Gemcitabine Hydrochloride, equivalent to 1.6 grams (1600 mg) of Gemcitabine

• Single-dose Infusmart vial (ready-to-infuse)

• Used in select patients requiring high doses due to:

  • Higher body surface area (BSA > 2.0 m²)

  • Specific oncologist-prescribed regimens

• Less commonly used due to higher concentration

• More expensive, not cost-effective for lower-dose patients

• May lead to overage or wastage if full dose isn’t required

• Gemcitabine Hydrochloride, equivalent to 1.4 grams (1400 mg) of Gemcitabine

• Lyophilized powder in a single-dose vial

• Requires reconstitution before IV administration

• Used in adult patients who need mid-level dosing (BSA-based)

• Effective for lung, pancreatic, and bladder cancer

• Less commonly stocked compared to Gemtaz

• Store below 25°C, protected from light

• Once opened or reconstituted: use immediately or within 24 hours if refrigerated (2–8°C)

Additional Information:

• Delivery Time: 12-15 days

Generic Name: Leuprolide Acetate
Strength: 3.75 mg
Formulation: Depot Injection
Manufacturer: Sun Pharma

📌 Indications:

• Prostate cancer (palliative treatment)

• Endometriosis

• Uterine fibroids

• Precocious puberty

🧬 Mechanism of Action:
Lupride is a GnRH agonist. It initially stimulates and then suppresses pituitary secretion of LH and FSH, leading to a reduction in testosterone (in men) and estrogen (in women).

💊 Dosage:

• Administered once every month via intramuscular injection.

• Often used in short-term hormonal suppression protocols.

⚠️ Common Side Effects:

• Hot flashes

• Mood changes

• Injection site pain

• Bone thinning (long-term use)

🟢 Widely Used Because:

• Suitable for monthly management

• Preferred for gynecological indications

• Cost-effective and widely available

Generic Name: Leuprolide Acetate
Strength: 7.5 mg
Formulation: Extended-release injectable gel
Manufacturer: Emcure Pharmaceuticals (among others)

📌 Indications:

• Advanced prostate cancer (palliative care)

🧬 Mechanism of Action:
Same as Lupride – suppresses LH/FSH after an initial surge, decreasing testosterone levels.

💊 Dosage:

• Injected once monthly, subcutaneously

• Comes in a pre-filled syringe with special delivery technology for sustained release

⚠️ Common Side Effects:

• Tumor flare (initially)

• Decreased libido

• Osteoporosis with long-term use

🔵 Usage:

• Used mainly for prostate cancer

• Less common than Lupride due to cost and specific indication

Generic Name: Leuprolide Acetate
Strength: 11.25 mg
Formulation: 3-Month Depot Injection
Manufacturer: Zydus Cadila

📌 Indications:

• Prostate cancer

• Endometriosis

• Uterine fibroids

🧬 Mechanism of Action:
Prolonged suppression of gonadotropins with quarterly administration.

💊 Dosage:

• Once every 3 months, intramuscularly

• Useful for patients preferring fewer injections

⚠️ Common Side Effects:

• Sweating

• Headache

• Emotional lability

• Reduced bone mineral density

Generic Name: Leuprolide Acetate
Strength: 22.5 mg
Formulation: 3–6 Month Depot
Manufacturer: Bharat Serums & Vaccines

📌 Indications:

• Advanced prostate cancer

• Endometriosis

• Uterine fibroids

🧬 Mechanism of Action:
Long-acting GnRH agonist formulation. Sustained suppression of hormone levels.

💊 Dosage:

• Administered every 3 to 6 months

• Suitable for chronic hormonal therapy

⚠️ Common Side Effects:

• Menopausal symptoms

• Bone loss

• Depression/anxiety

Additional Information:

• Delivery Time: 12-15 days

• Generic Name: Lomustine

• Brand: Lomoother

• Strength: 40 mg

• Dosage Form: Oral capsule

• Manufacturer: (Typically manufactured by Indian pharmaceutical companies; brand availability may vary by region)

Lomoother 40 mg contains Lomustine, an alkylating agent from the nitrosourea class. It is used as chemotherapy, particularly for cancers that affect the brain, lymphatic system, and lungs.

It works by interfering with the DNA and RNA synthesis in cancer cells, preventing them from dividing and leading to cell death.

Lomoother (Lomustine) is commonly used for:

• Brain tumors (e.g., glioblastoma multiforme, astrocytoma)

• Hodgkin's lymphoma (especially relapsed or refractory cases)

• Lung cancer (sometimes used off-label)

• Melanoma, colorectal, and ovarian cancers (off-label/investigational)

• Lomustine alkylates and carbamoylates DNA and RNA strands.

• This leads to cross-linking of DNA, inhibition of replication and transcription, and eventual cancer cell death.

• As a lipophilic compound, it crosses the blood-brain barrier, making it highly effective in treating brain tumors.

• Oral use only (taken by mouth)

• Dosed based on body surface area (BSA) — typically 40–130 mg/m² every 6 weeks

• Should be taken on an empty stomach (to reduce nausea)

• Single dose only every 6 weeks due to delayed bone marrow suppression

⚠️ Must not be repeated more frequently than recommended due to risk of severe bone marrow toxicity.

Common:

• Nausea, vomiting (can be prolonged)

• Loss of appetite

• Fatigue

• Hair loss (alopecia)

Serious:

• Bone marrow suppression (anemia, leukopenia, thrombocytopenia)

• Pulmonary fibrosis (rare but serious lung damage)

• Hepatotoxicity (liver damage)

• Kidney dysfunction with prolonged use

• Secondary malignancies (long-term use)

Bone marrow suppression is delayed and cumulative, peaking 4–6 weeks after dosing.

• CBC (complete blood count) regularly

• Liver and kidney function tests

• Chest X-ray or pulmonary function in long-term use

• Store in a cool, dry place below 25°C

• Keep away from children

• Do not crush or open capsules

• Typically 24 to 36 months if stored properly

• Effective against brain tumors due to ability to cross the blood-brain barrier

• Used in multi-agent chemotherapy protocols like PCV (Procarbazine, CCNU [Lomustine], and Vincristine)

• Gleostine (U.S. brand of Lomustine)

• CCNU (older brand)

• Procarbazine, Temozolomide (for brain tumors)

Additional Information:

• Delivery Time: 12-15 days

• Inhibits proliferation of myeloma cells

• Promotes apoptosis (cell death)

• Modulates cytokines, boosts T-cell and NK-cell activity

• Inhibits angiogenesis

• Multiple myeloma, in combination with low-dose dexamethasone

• For patients who have received:

  • ≥2 prior therapies (including lenalidomide and a proteasome inhibitor)

  • Shown disease progression

• Standard dose: 4 mg once daily for 21 days of a 28-day cycle

• Pomired 2 mg may be used for dose titration (e.g., 2 mg/day)

• Taken orally, with or without food

• Neutropenia, anemia, fatigue

• Infections (especially pneumonia)

• Thrombocytopenia, constipation, nausea

• Thromboembolic events (DVT/PE)

• Hetero is a reputable Indian oncology brand

• Pomired is widely used, often in government hospitals and mid-tier centers

• Commonly combined with dexamethasone or bortezomib

(Same as above – see Pomired)

• Used primarily for low-dose initiation or maintenance therapy

• Also helpful in elderly or renal-compromised patients where full dose is not tolerated

• Often part of titration regimens

• Used with weekly dexamethasone (e.g., 40 mg)

• Also combined with monoclonal antibodies (e.g., daratumumab)

Similar IMiD profile:

• Cytopenias, fatigue, DVT risk

• Monitor WBC, platelets, and hemoglobin

• Pomalomg is the most widely recognized brand in India

• Natco's strong clinical trust and oncology network contribute to top market share

• Available in 1 mg, 2 mg, 4 mg options, ensuring flexible dosing

• Often preferred in clinical trials and large corporate hospitals

Same as Pomired and Pomalomg

• Used as the standard full-dose pomalidomide therapy

• Especially in patients who tolerate higher doses or are in the active phase of combination therapy

• 4 mg/day for 21 days of a 28-day cycle

• Dose may be adjusted in renal/hepatic dysfunction

• Higher dose = higher risk of neutropenia, thrombocytopenia

• Infection risk increases—requires prophylactic antibiotics in some patients

• Pomyelo 4 mg is often used for the initial phase of therapy

• Dr. Reddy’s is well-established in oncology but Pomalomg dominates the pomalidomide space

• Moderately popular, especially where higher doses are needed initially

Additional Information:

• Delivery Time: 12-15 days

Axpero (Axitinib) is primarily used for the treatment of:

• Advanced Renal Cell Carcinoma (RCC) – especially in patients who have failed prior systemic therapy (e.g., sorafenib, sunitinib).

Axitinib selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are crucial in the process of angiogenesis (formation of new blood vessels). By blocking these pathways, Axitinib slows or stops the growth of blood vessels that supply tumors, thereby inhibiting tumor progression.

• Typical starting dose: 5 mg twice daily (though Axpero is a 1 mg tablet, doses are titrated or adjusted based on tolerance).

• Tablets should be taken approximately 12 hours apart, with or without food.

• Dose adjustments are often made depending on side effects and patient tolerance.

• Hypertension (high blood pressure)

• Diarrhea

• Fatigue

• Loss of appetite

• Hand-foot syndrome (palmar-plantar erythrodysesthesia)

• Nausea

• Weight loss

• Voice changes

• Cardiovascular Monitoring: Regular blood pressure checks are necessary.

• Hepatic Impairment: Dose adjustments may be needed.

• Thyroid Monitoring: Axitinib can alter thyroid function.

• Wound Healing Impairment: Treatment should be stopped temporarily before major surgery.

• Bleeding and Thrombotic Risks: Patients should be monitored closely.

• Approved for the treatment of advanced Renal Cell Carcinoma (RCC) in patients previously treated with other systemic therapies.

Functions identically to Axpero: inhibits VEGFR pathways, suppressing angiogenesis and thereby slowing tumor growth and spread.

• 5 mg twice daily is a standard initial dosage – hence Bdaxit 5 mg is often used without needing to combine multiple lower-dose tablets.

• Dosing is personalized based on tolerability, side effects, and clinical response.

• Can be taken with or without food.

• High blood pressure

• Gastrointestinal symptoms (nausea, diarrhea, loss of appetite)

• Weakness/fatigue

• Hand-foot skin reaction

• Dysphonia (voice changes)

• Weight loss

• Skin discoloration or dryness

• Cardiovascular: Careful monitoring for signs of heart-related side effects and high blood pressure.

• Liver and Kidney: Use with caution in hepatic or renal impairment.

• Surgical Considerations: Discontinue prior to planned surgery.

• Risk of Bleeding/Clots: Use with caution in at-risk patients.

Additional Information:

• Delivery Time: 12-15 days

• Hodgkin’s Lymphoma (often as part of the MOPP regimen)

• Primary CNS tumors (like gliomas and astrocytomas – off-label or protocol-driven)

• Occasionally used in other refractory lymphomas

• Works by inhibiting DNA, RNA, and protein synthesis

• Acts as a cytotoxic alkylating agent after hepatic activation

• Interferes with cell replication, leading to cell death, especially in rapidly dividing tumor cells

• Oral use, usually part of multi-agent chemotherapy

• In MOPP: Typically administered daily for 14 days, with dosage based on body surface area (BSA)

• Dose adjustments are made for renal/hepatic function and blood count monitoring

• Bone marrow suppression (leukopenia, thrombocytopenia)

• Gastrointestinal upset (nausea, vomiting, anorexia)

• CNS effects (lethargy, confusion)

• Secondary malignancies (with long-term exposure)

• Rare: Hypersensitivity reactions, neuropathy

• Store below 25°C, protected from light and moisture

• Keep out of reach of children

• Store in original packaging to maintain integrity

• Neon is a well-established oncology manufacturer in India

• HOD-PRO is moderately available in institutional oncology setups

• Used where Neon oncology lines are trusted or preferred (esp. in some govt. tenders)

• Hodgkin’s Lymphoma (as a key part of MOPP regimen)

• Malignant gliomas, high-grade brain tumors (with radiation or temozolomide)

• Sometimes in relapsed or refractory lymphomas

• Functions similarly to HOD-PRO, by alkylating DNA and RNA

• Causes cytotoxic damage through methylation and strand breakage

• Cell-cycle nonspecific agent

• Oral administration

• Standard: 100 mg/m²/day for 14 days in a 28-day cycle, per MOPP or other regimens

• Frequent CBC monitoring required due to risk of myelosuppression

• Myelosuppression (neutropenia, anemia)

• Gastrointestinal toxicity

• CNS symptoms (tremors, confusion, somnolence)

• Rare: Hepatotoxicity, infertility, secondary leukemia

• Store below 25°C, in a dry place

• Protect from light and moisture

• Use only under strict medical supervision

•  

Additional Information:

• Delivery Time: 12-15 days

Features:

• Effective
• Accurately composed
• Hygienically prepared and packed

• Available as 400mg tablets

• Symptoms like diarrhea and rash

• Should not be taken without consulting the doctor if the patient ever had pulmonary fibrosis (scarring of the lungs), or liver or kidney disease
• Not recommended if the patient is allergic to the medicine or any of its constituents
• Kindly notify the doctor immediately, if allergic reactions (difficulty breathing, closing of the throat, swelling of the lips, tongue, or face; or hives), lung problems, liver problems, eye problems, severe nausea, vomiting, loss of appetite, or diarrhea during treatment are noticed
• Doctor consultation recommended for pregnant women or for those who are breast feeding their child

• We are the Trader and Exporter of Anti Cancer Drugs. Our major market is South Asia which includes countries like China (major dealer), Thailand, Singapore, Hong Kong, Malaysia etc. We are also the Trader and Exporter of Anti Cancer Medicines in South Africa, Brazil, North America and South America.